Multi-institutional studies of the national cardiovascular center ventricular assist system: Use in 92 patients

H. Takano, Y. Taenaka, H. Noda, M. Kinoshita, A. Yagura, E. Tasum i, H. Sekii, E. Sasaki, Mitsuo Umezu, T. Nakatani, S. Kyo, R. Omoto, T. Akutsu, H. Manabe

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

A ventricular assist system (VAS) developed at the National Cardiovascular Center (NCVC) and produced by Toyobo Company has been clinically evaluated at 32 institutes. The system consists of a pneumatic and diaphragm-type pump, and a control-drive unit with an automatic bypass flow (BF) control system. The VAS was used in 85 adults and 7 children with acute, severe heart failure. Forty-eight patients were weaned from VAS, and 21 were long-term survivors. Heparin was not used when BF was above 2.0 L/min in an adult sized pump, and 0.8 in a pediatric one. Thrombus formation was noticed in the groove around the valve in eight cases, and in the pump in eight. Pump-originated serious complications were not seen. Hematologic and biochemical findings revealed that the VAS did not directly affect the major organs. The control-drive unit, including the automatic BF control system, functioned accurately, with less manpower, securing reliable control over the circulation. Two major causes of death were irreversible heart failure, and multiple organ failure, which resulted from delayed application. In conclusion, the NCVC-type VAS has been found effective and reliable, less thrombogenic, and requiring less manpower for its clinical use.

Original languageEnglish
Pages (from-to)541-544
Number of pages4
JournalASAIO Transactions
Volume35
Issue number3
Publication statusPublished - 1989 Jul
Externally publishedYes

Fingerprint

Heart Failure
Pumps
Multiple Organ Failure
Diaphragm
Flow control
Survivors
Heparin
Cause of Death
Thrombosis
Pediatrics
Control systems
Diaphragms
Pneumatics
Industry

ASJC Scopus subject areas

  • Biophysics

Cite this

Takano, H., Taenaka, Y., Noda, H., Kinoshita, M., Yagura, A., Tasum i, E., ... Manabe, H. (1989). Multi-institutional studies of the national cardiovascular center ventricular assist system: Use in 92 patients. ASAIO Transactions, 35(3), 541-544.

Multi-institutional studies of the national cardiovascular center ventricular assist system : Use in 92 patients. / Takano, H.; Taenaka, Y.; Noda, H.; Kinoshita, M.; Yagura, A.; Tasum i, E.; Sekii, H.; Sasaki, E.; Umezu, Mitsuo; Nakatani, T.; Kyo, S.; Omoto, R.; Akutsu, T.; Manabe, H.

In: ASAIO Transactions, Vol. 35, No. 3, 07.1989, p. 541-544.

Research output: Contribution to journalArticle

Takano, H, Taenaka, Y, Noda, H, Kinoshita, M, Yagura, A, Tasum i, E, Sekii, H, Sasaki, E, Umezu, M, Nakatani, T, Kyo, S, Omoto, R, Akutsu, T & Manabe, H 1989, 'Multi-institutional studies of the national cardiovascular center ventricular assist system: Use in 92 patients', ASAIO Transactions, vol. 35, no. 3, pp. 541-544.
Takano H, Taenaka Y, Noda H, Kinoshita M, Yagura A, Tasum i E et al. Multi-institutional studies of the national cardiovascular center ventricular assist system: Use in 92 patients. ASAIO Transactions. 1989 Jul;35(3):541-544.
Takano, H. ; Taenaka, Y. ; Noda, H. ; Kinoshita, M. ; Yagura, A. ; Tasum i, E. ; Sekii, H. ; Sasaki, E. ; Umezu, Mitsuo ; Nakatani, T. ; Kyo, S. ; Omoto, R. ; Akutsu, T. ; Manabe, H. / Multi-institutional studies of the national cardiovascular center ventricular assist system : Use in 92 patients. In: ASAIO Transactions. 1989 ; Vol. 35, No. 3. pp. 541-544.
@article{95c1591cf6774e859f91b843e1d8bf55,
title = "Multi-institutional studies of the national cardiovascular center ventricular assist system: Use in 92 patients",
abstract = "A ventricular assist system (VAS) developed at the National Cardiovascular Center (NCVC) and produced by Toyobo Company has been clinically evaluated at 32 institutes. The system consists of a pneumatic and diaphragm-type pump, and a control-drive unit with an automatic bypass flow (BF) control system. The VAS was used in 85 adults and 7 children with acute, severe heart failure. Forty-eight patients were weaned from VAS, and 21 were long-term survivors. Heparin was not used when BF was above 2.0 L/min in an adult sized pump, and 0.8 in a pediatric one. Thrombus formation was noticed in the groove around the valve in eight cases, and in the pump in eight. Pump-originated serious complications were not seen. Hematologic and biochemical findings revealed that the VAS did not directly affect the major organs. The control-drive unit, including the automatic BF control system, functioned accurately, with less manpower, securing reliable control over the circulation. Two major causes of death were irreversible heart failure, and multiple organ failure, which resulted from delayed application. In conclusion, the NCVC-type VAS has been found effective and reliable, less thrombogenic, and requiring less manpower for its clinical use.",
author = "H. Takano and Y. Taenaka and H. Noda and M. Kinoshita and A. Yagura and {Tasum i}, E. and H. Sekii and E. Sasaki and Mitsuo Umezu and T. Nakatani and S. Kyo and R. Omoto and T. Akutsu and H. Manabe",
year = "1989",
month = "7",
language = "English",
volume = "35",
pages = "541--544",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Multi-institutional studies of the national cardiovascular center ventricular assist system

T2 - Use in 92 patients

AU - Takano, H.

AU - Taenaka, Y.

AU - Noda, H.

AU - Kinoshita, M.

AU - Yagura, A.

AU - Tasum i, E.

AU - Sekii, H.

AU - Sasaki, E.

AU - Umezu, Mitsuo

AU - Nakatani, T.

AU - Kyo, S.

AU - Omoto, R.

AU - Akutsu, T.

AU - Manabe, H.

PY - 1989/7

Y1 - 1989/7

N2 - A ventricular assist system (VAS) developed at the National Cardiovascular Center (NCVC) and produced by Toyobo Company has been clinically evaluated at 32 institutes. The system consists of a pneumatic and diaphragm-type pump, and a control-drive unit with an automatic bypass flow (BF) control system. The VAS was used in 85 adults and 7 children with acute, severe heart failure. Forty-eight patients were weaned from VAS, and 21 were long-term survivors. Heparin was not used when BF was above 2.0 L/min in an adult sized pump, and 0.8 in a pediatric one. Thrombus formation was noticed in the groove around the valve in eight cases, and in the pump in eight. Pump-originated serious complications were not seen. Hematologic and biochemical findings revealed that the VAS did not directly affect the major organs. The control-drive unit, including the automatic BF control system, functioned accurately, with less manpower, securing reliable control over the circulation. Two major causes of death were irreversible heart failure, and multiple organ failure, which resulted from delayed application. In conclusion, the NCVC-type VAS has been found effective and reliable, less thrombogenic, and requiring less manpower for its clinical use.

AB - A ventricular assist system (VAS) developed at the National Cardiovascular Center (NCVC) and produced by Toyobo Company has been clinically evaluated at 32 institutes. The system consists of a pneumatic and diaphragm-type pump, and a control-drive unit with an automatic bypass flow (BF) control system. The VAS was used in 85 adults and 7 children with acute, severe heart failure. Forty-eight patients were weaned from VAS, and 21 were long-term survivors. Heparin was not used when BF was above 2.0 L/min in an adult sized pump, and 0.8 in a pediatric one. Thrombus formation was noticed in the groove around the valve in eight cases, and in the pump in eight. Pump-originated serious complications were not seen. Hematologic and biochemical findings revealed that the VAS did not directly affect the major organs. The control-drive unit, including the automatic BF control system, functioned accurately, with less manpower, securing reliable control over the circulation. Two major causes of death were irreversible heart failure, and multiple organ failure, which resulted from delayed application. In conclusion, the NCVC-type VAS has been found effective and reliable, less thrombogenic, and requiring less manpower for its clinical use.

UR - http://www.scopus.com/inward/record.url?scp=0024705692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024705692&partnerID=8YFLogxK

M3 - Article

C2 - 2597528

AN - SCOPUS:0024705692

VL - 35

SP - 541

EP - 544

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 3

ER -